A M de Pinho1, G Santoro-Lopes, L H Harrison, M Schechter. 1. Infectious Diseases Service, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Abstract
OBJECTIVE: To study the impact of chemoprophylaxis for tuberculosis on the survival of HIV-infected patients with a positive tuberculin skin test. DESIGN: Prospective observational cohort study. SETTING: Outpatient clinic of a university hospital, in Rio de Janeiro, Brazil. PATIENTS: Two-hundred and ninety-seven patients with a positive tuberculin skin test (reaction > or = 5mm) who were admitted to the cohort between January 1991 and December 1994. Follow-up ended on September 30, 1998. INTERVENTION: The use of chemoprophylaxis for tuberculosis. MAIN OUTCOME MEASURES: Death was the primary outcome variable. The occurrence of tuberculosis was studied as a secondary outcome. Cox regression models were used in these analyses. RESULTS: The median follow-up time was 43.6 months. Chemoprophylaxis was used by 128 (43%) of the patients. The use of chemoprophylaxis was associated with a reduction in risk for tuberculosis (hazard ratio, 0.38; 95% confidence interval, 0.14-1.04; P = 0.05). In a regression model adjusted for baseline CD4 cell count, chemoprophylaxis was associated with longer survival (hazard ratio, 0.24; 95% confidence interval, 0.09-0.65; P = 0.002). CONCLUSIONS: Anti-tuberculosis chemoprophylaxis was associated with a substantially prolonged survival among purified protein derivative-positive HIV-infected patients in Brazil. These data have important implications for the clinical care of patients with HIV infection in areas of the world with a high prevalence of Mycobacterium tuberculosis infection.
OBJECTIVE: To study the impact of chemoprophylaxis for tuberculosis on the survival of HIV-infectedpatients with a positive tuberculin skin test. DESIGN: Prospective observational cohort study. SETTING:Outpatient clinic of a university hospital, in Rio de Janeiro, Brazil. PATIENTS: Two-hundred and ninety-seven patients with a positive tuberculin skin test (reaction > or = 5mm) who were admitted to the cohort between January 1991 and December 1994. Follow-up ended on September 30, 1998. INTERVENTION: The use of chemoprophylaxis for tuberculosis. MAIN OUTCOME MEASURES: Death was the primary outcome variable. The occurrence of tuberculosis was studied as a secondary outcome. Cox regression models were used in these analyses. RESULTS: The median follow-up time was 43.6 months. Chemoprophylaxis was used by 128 (43%) of the patients. The use of chemoprophylaxis was associated with a reduction in risk for tuberculosis (hazard ratio, 0.38; 95% confidence interval, 0.14-1.04; P = 0.05). In a regression model adjusted for baseline CD4 cell count, chemoprophylaxis was associated with longer survival (hazard ratio, 0.24; 95% confidence interval, 0.09-0.65; P = 0.002). CONCLUSIONS: Anti-tuberculosis chemoprophylaxis was associated with a substantially prolonged survival among purified protein derivative-positive HIV-infectedpatients in Brazil. These data have important implications for the clinical care of patients with HIV infection in areas of the world with a high prevalence of Mycobacterium tuberculosis infection.
Authors: Jonathan E Golub; Silvia Cohn; Valeria Saraceni; Solange C Cavalcante; Antonio G Pacheco; Lawrence H Moulton; Betina Durovni; Richard E Chaisson Journal: Clin Infect Dis Date: 2014-11-02 Impact factor: 9.079
Authors: Betina Durovni; Solange C Cavalcante; Valeria Saraceni; Vitoria Vellozo; Giselle Israel; Bonnie S King; Silvia Cohn; Anne Efron; Antonio G Pacheco; Lawrence H Moulton; Richard E Chaisson; Jonathan E Golub Journal: AIDS Date: 2010-11 Impact factor: 4.177
Authors: Anand A Date; Marco Vitoria; Reuben Granich; Mazuwa Banda; Mayada Youssef Fox; Charlie Gilks Journal: Bull World Health Organ Date: 2009-10-23 Impact factor: 9.408
Authors: Hyun J Lim; Alphonse Okwera; Harriet Mayanja-Kizza; Jerrold J Ellner; Roy D Mugerwa; Christopher C Whalen Journal: HIV Clin Trials Date: 2006 Jul-Aug
Authors: Valeria Saraceni; Silvia Cohn; Solange C Cavalcante; Antonio G F Pacheco; Lawrence H Moulton; Richard E Chaisson; Betina Durovni; Jonathan E Golub Journal: J Acquir Immune Defic Syndr Date: 2014-09-01 Impact factor: 3.731
Authors: Jonathan E Golub; Jacquie Astemborski; Mohammed Ahmed; Wendy Cronin; Shruti H Mehta; Gregory D Kirk; David Vlahov; Richard E Chaisson Journal: J Acquir Immune Defic Syndr Date: 2008-12-15 Impact factor: 3.731
Authors: Jonathan E Golub; Valeria Saraceni; Solange C Cavalcante; Antonio G Pacheco; Lawrence H Moulton; Bonnie S King; Anne Efron; Richard D Moore; Richard E Chaisson; Betina Durovni Journal: AIDS Date: 2007-07-11 Impact factor: 4.177
Authors: Jonathan E Golub; Betina Durovni; Bonnie S King; Solange C Cavalacante; Antonio G Pacheco; Lawrence H Moulton; Richard D Moore; Richard E Chaisson; Valeria Saraceni Journal: AIDS Date: 2008-11-30 Impact factor: 4.177